Teva Agrees to Pay $225 Million to Settle U.S. Price-Fixing Charges - The Wall Street Journal
wsj.comSubmitted by thewallstreetjournal7221 in business
Generic drugmaker’s U.S. unit also must sell drug line for cholesterol treatment pravastatin
Submitted by thewallstreetjournal7221 in business
Generic drugmaker’s U.S. unit also must sell drug line for cholesterol treatment pravastatin